Drug intelligence / Profile preview

A-98881

Development stage: Discontinued
Lead developer: Abbott
Modality: Small Molecules

Overview

A-98881 is a small molecule drug developed as an HIV-1 protease inhibitor. It belongs to the class of methoxyphenols and was initially developed by Abbott Laboratories for the treatment of HIV infections. The compound acts by inhibiting the activity of HIV-1 protease, an essential enzyme required for viral replication. Despite its promising mechanism, development was discontinued at the preclinical stage and it did not advance to clinical trials or receive regulatory approval[2][3][1].

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on A-98881.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A-98881.

Explore the full profile